Introduction
This erratum provides essential corrections to the quantitative data and visual evidence originally published regarding the therapeutic efficacy of the humanized monoclonal antibody hu1A12. The study focuses on neutralizing Osteopontin (OPN), a secreted protein that promotes tumor progression, metastasis, and survival in breast cancer. By humanizing the antibody, researchers aimed to create a treatment compatible with the human immune system, thereby reducing rejection risks and enhancing therapeutic longevity.
Methods and Experimental Validation
The efficacy of hu1A12 was evaluated using several standard molecular biology techniques:
- Cell Proliferation: Measured via $[^3H]$thymidine uptake in MDA-MB-435S breast cancer cells.
- Apoptotic Signaling: Western blotting was employed to assess the expression of Bax (pro-apoptotic) and Bcl-2 (anti-apoptotic) proteins.
- Transcription Factor Activity: Electrophoretic Mobility Shift Assay (EMSA) tracked the activity of NF-$\kappa$B, a key factor in cancer cell survival.
- Morphological Analysis: Fluorescence microscopy visualized nuclear changes indicative of apoptosis.
Key Results and Corrections
The primary purpose of this update is to correct numerical errors that previously underestimated the potency of both OPN and the hu1A12 antibody.
Enhanced Potency of OPN and hu1A12
The corrected data reveals that OPN stimulation increases $[^3H]$thymidine uptake by 5.02 ± 0.94-fold, significantly higher than the initially reported 3.08-fold. Consequently, the inhibitory effect of the hu1A12 antibody is also more substantial, reducing uptake by 3.17 ± 0.62-fold (corrected from 2.76-fold).
Modulation of Survival Pathways
As shown in the corrected Figure 1 (panels C and D), hu1A12 treatment fundamentally alters the cell's internal signaling. The antibody effectively reduces NF-$\kappa$B DNA-binding activity and shifts the ratio of Bax to Bcl-2 proteins. By decreasing the anti-apoptotic Bcl-2 and maintaining or increasing pro-apoptotic Bax, hu1A12 "re-arms" the cancer cells' internal machinery to undergo programmed cell death (apoptosis).
Conclusion
The corrections provided in this erratum reinforce the potential of hu1A12 as a potent inhibitor of OPN-mediated breast cancer progression. The updated fold-change values provide a more accurate benchmark for the antibody's efficacy in modulating critical survival pathways like NF-$\kappa$B and the Bcl-2 family of proteins. These findings support the continued development of hu1A12 toward clinical applications.
Summary updated